Labcorp stock gained 1.28 percent before October 28 results
Labcorp stock saw a 1.28 percent gain, reaching USD 308.49 on October 2, 2026, ahead of its third-quarter results release scheduled for October 28, 2026. The company reported Q2 revenue of USD 3.73 billion, a 5.8 percent increase year-over-year, and reaffirmed its long-term financial guidance despite potential regulatory payment cuts. Its stock price remains below its 52-week high, with investors weighing revenue growth against reimbursement uncertainties.
Truist raises target for Labcorp stock to USD 365.00
Truist Financial has raised its price target for Labcorp (LH) stock from $350.00 to $365.00, maintaining a Buy rating. This adjustment comes after Labcorp reported strong second-quarter 2026 results, including a 5.80% revenue increase and a 14.90% rise in adjusted earnings per share. The company also updated its full-year guidance, and its next earnings report is scheduled for October 28, 2026.
Quest Diagnostics Incorporated (DGX) Latest Stock News & Headlines
This article provides the latest news and headlines for Quest Diagnostics (DGX), including its stock performance and recent announcements. Key updates include a declared cash dividend, clinical performance demonstrations for Haystack MRD®, and a new heart screening program in Florida. The company's stock has seen significant gains year-to-date, despite concerns about potential Medicare payment cuts.
Labcorp Holdings Inc. (NYSE:LH) Stock Has Average Price Target of $337.73 According to Brokerages
Labcorp Holdings Inc. (NYSE:LH) has an average price target of $337.73 from brokerages, with analysts maintaining a "Moderate Buy" rating. The company exceeded quarterly expectations, reporting $4.99 EPS and $3.73 billion in revenue, and declared a quarterly dividend of $0.72 per share. Insider selling of 8,593 shares worth approximately $2.7 million was reported last quarter.
The Galleri MCD vote: What FDA asked its advisors to ignore
This podcast episode discusses the FDA's advisory committee meeting on GRAIL Inc.'s multi-cancer detection test, Galleri. The FDA instructed its advisors to ignore clinical benefit claims and focus solely on the test's ability to detect cancers in asymptomatic individuals, sparking debate about the role of mortality reduction in test approvals and the appropriate nomenclature for "early detection." The episode highlights concerns about public perception, potential over-testing, and the broader implications for cancer screening regulations, particularly regarding the term "early detection."
Labcorp (LH) Sets Q3 2026 Earnings Release Date and Webcast
Labcorp (NYSE: LH) announced it will release its third-quarter 2026 financial results before market open on Wednesday, October 28, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss the results, which will also be posted on its Investor Relations website. GuruFocus estimates Labcorp's fair value at $275.32, with a GF Score of 79/100, and notes that 12 gurus currently hold the stock.
A 9 a.m. ET webcast will discuss Labcorp's third-quarter results on Oct. 28.
Labcorp Holdings (NYSE: LH) is set to release its third-quarter 2026 financial results before the market opens on October 28, 2026. A webcast will be held at 9:00 a.m. ET on the same day to discuss these results, which will be accessible via their investor relations website. A replay of the webcast will also be available for one year.
Labcorp to release Q3 2026 earnings on Oct 28 with webcast for investors.
Labcorp Holdings Inc. is scheduled to announce its third-quarter 2026 financial results on October 28 before the market opens, followed by a webcast for investors at 9:00 a.m. ET. This report is significant for those tracking the healthcare and diagnostics sectors, given Labcorp's global leadership in laboratory services. A market snapshot shows mixed performance for health-sector US stocks as of September 30, 2026.
Labcorp to report Q3 2026 results Oct. 28, will webcast earnings at 9:00 a.m. ET
Labcorp (LH) is scheduled to release its third-quarter 2026 financial results before the market opens on October 28, 2026. The company will also host a live webcast at 9:00 a.m. ET on the same day to discuss the results and provide investor commentary. Earnings materials and webcast access will be available on Labcorp’s investor relations website, with a replay accessible for one year.
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
Labcorp (NYSE: LH) is scheduled to announce its third-quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. Following the release, the company will host a conference call and webcast to discuss the results and provide an update on its business. Interested parties can access the call live or via replay.
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
Labcorp Holdings Inc. (NYSE: LH) will release its financial results for the third quarter of 2026 before the market opens on Wednesday, October 28, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss the results. The earnings press release and webcast link will be available on the Labcorp Investor Relations website.
Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History
This Yahoo Finance article provides a detailed overview of Medpace Holdings, Inc. (MEDP), including its stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's role as a clinical research organization offering drug and medical device development services globally. The article also presents performance comparisons against the S&P 500 and recent earnings trends.
Fortrea Beats Investor Suit Over Labcorp Spinoff Woes
A New York federal judge has dismissed a proposed shareholder class action against clinical research company Fortrea Holdings Inc. The lawsuit alleged that Fortrea overstated its business model's strength following its spin-off from Labcorp Holdings Inc. The court ruled that the statements made by the defendants did not sufficiently plead securities fraud.
Labcorp stock after-hours: no euro price or percentage
Labcorp stock had no dated euro price or percentage reported after-hours, following the company's disclosure of a multistate settlement for a 2019 data breach involving its debt collector. The settlement, totaling over $2.2 million, requires improved information security practices. Labcorp also reaffirmed its 2026 financial guidance and outlined a long-term outlook through 2029 with projected revenue and EPS growth.
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
Labcorp (LH) is expanding into high-growth specialty testing markets and leveraging AI for operational efficiency, which has led to a 23.4% year-to-date stock rise. Despite positive developments like strategic acquisitions and partnerships, the company faces headwinds from macroeconomic uncertainty, cost inflation, and changing reimbursement policies. Analysts show a positive outlook for 2026 earnings and revenue, but investors should weigh these factors carefully.
LH4204171 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the LH4204171 corporate bond issued by Laboratory Corporation of America Holdings, focusing on its coupon payments and redemption information. It outlines key facts such as issuer details, issue and maturity dates, face value, and the company's business segments. The profile also includes specifics on interest payment schedules, next coupon dates, and bond redemption information.
Labcorp stock last trades at USD 309.47 on September 28, 2026
Labcorp stock closed at USD 309.47 on the NYSE on September 28, 2026, a slight decrease of 0.05 percent. This follows the company's Investor Day on September 10, where it reaffirmed its 2026 outlook and presented its long-term financial strategy through 2029. The company's common stock trades under the symbol LH.
Labcorp stock reports 2026 growth targets amid reimbursement risk
Labcorp (ISIN US50540R4092) closed at USD 309.64 on September 25, 2026, with a market value of USD 25.4 billion. Despite a potential Medicare reimbursement cut of up to 15% from 2027, the company reaffirmed its 2026 revenue guidance of USD 14.71 billion to USD 14.83 billion and expects 5.00% to 8.00% compound annual revenue growth through 2029. The Q2 2026 results exceeded consensus, showing adjusted EPS of USD 4.99 against USD 4.78.
MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer Diagnostics
DataMeds AI Inc. (MEDS) stock has surged by 25.4% following its acquisition of Helomics, an AI cancer diagnostics lab, and a settlement that removed significant liabilities. The company is pivoting towards oncology diagnostics and has engaged in new partnerships, fueling speculative trading interest despite its early-stage and unprofitable financial status. Traders are closely watching MEDS due to its recent fundamental reset and multiple narrative catalysts.
Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run
Guardant Health (GH) has seen its stock increase fivefold over the past three years, prompting questions about whether its current valuation is supported by future cash flows. The company's recent expansion of coverage for its Shield blood test is expected to boost future cash inflows significantly, with analysts forecasting a move from current cash burning to substantial free cash generation by the early 2030s, which could justify its current share price of $177.25. However, there are differing views, with some narratives suggesting the stock is undervalued by 9% due to AI integration, while others indicate it could be overvalued by 17% due to reimbursement challenges.
Wisconsin Joins $2.3M Labcorp Data Breach Settlement
Wisconsin has joined a 44-state settlement with Labcorp, resolving a 2019 data breach that originated at a third-party debt collector, AMCA, and affected over 27.5 million people nationwide, including 16,615 Wisconsin residents. The settlement requires Labcorp to pay $2.3 million and implement significant reforms to its vendor security and data management practices. This case highlights a growing regulatory focus on holding companies accountable for vendor-related data exposures.
FDA panel endorses Grail Galleri multi-cancer blood test
An FDA advisory panel has recommended Grail Inc.'s Galleri multi-cancer blood test, marking the first time such a federal group has endorsed a multi-cancer detection test. The panel unanimously supported the test's safety, split on its effectiveness, and ultimately concluded that its benefits outweigh its risks for adults 50 and older. The FDA's final decision on nationwide commercial availability is expected within months, though the advisory panel's recommendations are not binding.
US50540RAZ55 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the US50540RAZ55 bond issued by Laboratory Corporation of America Holdings. It outlines key facts such as the issuer, issue and maturity dates, face value, and minimum denomination. The bond has a fixed coupon rate of 4.35% paid semi-annually, with a redemption amount of $650.00 million USD.
New blood test can detect more than 50 types of cancer. Here’s what to know
Federal health advisers have endorsed Grail Inc.'s Galleri blood test, which can detect signs of over 50 types of cancer in healthy individuals, though they cautioned about its limitations. The advisory panel voted that the test offers potential benefits despite concerns about false positives or negatives, and noted that more research is needed to prove its effectiveness for early detection. If the FDA approves it, widespread U.S. adoption could follow, making it more accessible through insurance coverage, but it should be used in conjunction with, not as a replacement for, existing cancer screenings.
Labcorp Holdings (LH) After Investor Day And Higher Guidance Is It Fully Valued
Labcorp Holdings (LH) recently held its 2026 Investor Day, where management raised full-year revenue and adjusted EPS guidance, focusing on specialty diagnostics and biopharma lab services. Despite a recent slip in share price over the past month, the stock has performed well over 90 days and year-to-date, with longer-term holders seeing strong returns. The company is considered 10% undervalued by some analysts, with a fair value of $344.25, driven by its expansion in high-value specialty testing.
BrightSpring Health Services (BTSG) Short Interest & Short Float | Updated Sep 2026
As of September 15, 2026, BrightSpring Health Services (BTSG) had a short interest of 10.18 million shares, representing 5.30% of its public float, which is a 0.36% increase from the prior report. The short interest ratio is 4.6 days to cover, indicating it would take 4.6 days of average trading volume to cover all short positions. The article provides a historical table of short interest data and answers frequently asked questions about BTSG's short interest metrics and comparison to competitors.
Labcorp Reaffirms Long-Term Earnings Outlook
The article states that Labcorp (LH) has reaffirmed its long-term earnings outlook. Further details on the specific outlook or financial figures are not provided in the snippet.
F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
An FDA advisory committee has recommended approval for Grail's Galleri blood test, designed to detect various cancers early, despite concerns from doctors regarding its efficacy. Although hundreds of thousands have used the test, there's no data from randomized controlled trials showing it reduces cancer deaths, and a large trial in the U.K. failed to show a reduction in advanced cancer diagnoses. The test currently costs $949 out-of-pocket, but successful lobbying could lead to Medicare coverage starting in 2028 if FDA approval is granted.
FDA panel endorses first-of-a-kind cancer blood test from Grail
A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test for detecting signs of various cancers in healthy individuals, despite acknowledging uncertainties about its effectiveness and the need for further study. The panel voted 7-2 that the benefits outweigh the risks, paving the way for potential widespread adoption if the FDA agrees, though they stressed it should supplement, not replace, existing cancer screenings.
Labcorp Holdings Inc. (LH) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Labcorp Holdings Inc. (LH), including its current stock price, financial statistics, historical data, and recent news. The company, a diagnostics and research healthcare provider, offers various laboratory services and has recently highlighted strategic priorities for growth and shareholder value. The article also includes performance comparisons against the S&P 500 and analyst insights, with Truist Securities maintaining a "Buy" rating and raising the price target to $365.
FDA advisory panel recommends a first: multi-cancer blood test
An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.
Pediatrix Medical Group, Inc. (MD) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial information for Pediatrix Medical Group, Inc. (MD), including its stock price, historical data, performance metrics against the S&P 500, earnings trends, and analyst insights. The company, which provides newborn, maternal-fetal, and other pediatric subspecialty care, shows a current stock price of $25.86, with recent positive returns over 1-year and 3-year periods. Analyst recommendations are mixed, with an average target price of $26.33.
Charles River Labs stock rises 2.19 percent ahead of the open
Charles River Labs (ISIN US1591881009, Nasdaq: CRL) stock rose 2.19 percent to USD 285.11 on September 22, 2026, outperforming competitors like Labcorp and Quest Diagnostics. This move occurred alongside a mixed session for US equities, with the S&P 500 slightly down and the Nasdaq Composite reaching a record close. The article reports on the stock's performance ahead of the next US trading session.
Labcorp reaffirms long-term outlook despite preliminary CMS payment cuts
Labcorp (LH) has reaffirmed its 2026-2029 long-term outlook, despite preliminary Medicare payment cuts for laboratory services announced by the CMS. The company expects sustained growth in revenue, operating margin, EPS, and free cash flow, having already factored such reimbursement pressures into its guidance. Labcorp also highlighted the negative impact of these cuts on patient access and continues to support the bipartisan RESULTS Act.
Labcorp stock falls as CMS proposes 15 percent reimbursement cuts
Labcorp stock fell 5.9 percent in premarket trading after the Centers for Medicare and Medicaid Services (CMS) proposed reimbursement cuts of up to 15 percent for laboratory services. This policy creates a direct earnings risk for Labcorp and other diagnostic-testing companies. Despite this, Truist Securities raised Labcorp's price target, indicating that analysts are balancing regulatory pressure with the company's long-term fundamentals.
Why Labcorp Holdings Stock Dropped Today
Labcorp Holdings (NYSE: LH) stock dropped 3.3% after the Centers for Medicare & Medicaid Services (CMS) announced a 15% reduction in reimbursement rates for lab costs, effective January 1, 2027. This change is expected to save taxpayers $1 billion annually but will impact Labcorp's revenue. The company's 10-K filing had previously identified such reductions as a key risk, noting that CMS revenue constitutes about 8% of its total.
Perspective: First-Void Urine - A New Era in Accessible STI Testing
This article, titled "Perspective: First-Void Urine - A New Era in Accessible STI Testing," highlights the potential of first-void urine as a more accessible and convenient method for STI testing. It suggests that this approach could usher in a new era for improving public health by making testing easier for individuals.
Is Quest Diagnostics Stock Outperforming the Nasdaq?
Quest Diagnostics (DGX) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, year-to-date, and over the last 52 weeks, driven by growth in core routine testing and advanced diagnostics. The company's strategic acquisitions, partnerships, and consumer-initiated testing have further strengthened its market position. Analysts maintain a "Moderate Buy" rating for DGX, with a modest upside potential from current price levels.
S&P 500 Futures Steady in Premarket Trading; First Citizens Bcshs A, Labcorp Holdings Lag
In premarket trading, S&P 500 futures showed steady movement. Vicor Corp. (VICR) was up 9.6% and On Holding AG (ONON) rose 6.3% ahead of the U.S. stock market open. Meanwhile, First Citizens Bcshs A and Labcorp Holdings were lagging.
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics is surpassing its growth targets, driven by strong organic growth, increased consumer-health demand, and strategic partnerships. CEO Jim Davis noted that the company's revenue and earnings growth are exceeding previous projections, with significant contributions from its direct-to-consumer operations and health-system collaborations. The company is also navigating potential impacts from the PAMA Act while expanding its market presence and integration efforts.
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services
Shares of Quest Diagnostics (DGX) and Labcorp (LH) declined in premarket trading after Medicare indicated impending cuts to payment rates for laboratory services. This news suggests potential financial pressures for these major diagnostic companies. The full article is premium content, requiring a subscription to read.
Nykredit A S Buys Shares of 23,785 Labcorp Holdings Inc. $LH
Nykredit A/S recently acquired 23,785 shares of Labcorp Holdings Inc. (NYSE:LH) worth approximately $6.66 million during the second quarter. Other institutional investors also adjusted their holdings, with 95.94% of the company's stock now owned by institutional investors and hedge funds. Labcorp reported strong quarterly results, beating analyst expectations with EPS of $4.99 and revenue of $3.73 billion, and analysts maintain a "Moderate Buy" rating with an average price target of $337.73.
Labcorp stock heads into the open after holding at USD 323.97
Labcorp stock closed at USD 323.97 on September 15, 2026, marking a 2.75% increase on the New York Stock Exchange after investors reacted positively to Q2 2026 results and raised guidance. The stock traded within a range of USD 319 to USD 325, with revenues for Q2 2026 reported at USD 3.73 billion. Heading into the current trading day, Q2 2026 results remain the key fundamental reference point for investors.
Labcorp Holdings (LH) Moved Higher, What Is Driving Attention Now?
Labcorp Holdings (LH) has seen its stock price increase significantly, driven by an acquisition-focused strategy, reaffirmed multi-year guidance, and new cancer-focused partnerships and AI diagnostics. Despite this momentum, the company is considered only 4% undervalued by analysts, suggesting limited upside unless its AI and acquisition story fully plays out. The article highlights both growth drivers like innovative tests and AI-enhanced efficiencies, and risks such as regulatory shifts and pricing pressures.
Baird Financial Group Inc. Purchases 5,966 Shares of Labcorp Holdings Inc. $LH
Baird Financial Group Inc. significantly increased its stake in Labcorp Holdings Inc. by 144.8% in the second quarter, acquiring 5,966 additional shares and bringing its total holdings to $2.8 million. Institutional investors now own 95.94% of Labcorp, which has an average "Moderate Buy" rating and a consensus price target of $336.36 from analysts. The company also reported strong quarterly earnings, exceeding expectations, and announced a quarterly dividend of $0.72 per share.
Cerenome Names Samantha Fowlkes to Lead CNSide Commercial Sales
Cerenome Inc. (Nasdaq: CNSY) has appointed Samantha Fowlkes as vice president and head of commercial sales for its CNSide Diagnostics division. Fowlkes will lead the expansion and adoption of the company’s cerebrospinal fluid-based testing platform, CNSide, leveraging her two decades of experience in oncology diagnostics and precision medicine. Her role is crucial for strengthening relationships across oncology and pathology, increasing the platform's use, and building the commercial infrastructure for growth.
AMN Healthcare Survey Reveals Critical Divide Between Healthcare Leaders and Frontline Workers
A new AMN Healthcare survey reveals a critical divide between healthcare leaders' perceptions and frontline workers' experiences regarding organizational conditions. The 2026 Healthcare Workforce Outlook Survey, encompassing 4,040 professionals, shows that while commitment to patient care remains high, significant issues like staffing, workload, and leadership gaps threaten the healthcare system's future readiness. The survey introduces a Healthcare Workforce Outlook Index, highlighting low confidence in future demands despite moderate current engagement, and underscores the urgent need for integrated workforce strategies to address these challenges.
Labcorp (Laboratory Corporation of America Holdings) rStock (RLH) Price Prediction for 2026 to 2031
This article provides a price prediction for Labcorp (Laboratory Corporation of America Holdings) rStock (RLH) from 2026 to 2031, based on Bybit AI's Consensus Ratings and historical patterns. It highlights that Bybit AI estimates RLH to reach approximately $0.00 by 2030, with potential long-term growth. The article also includes a disclaimer about the significant market risks associated with cryptocurrency investments and advises investors to seek professional consultation.
Labcorp Holdings Inc. $LH Shares Purchased by Tidal Investments LLC
Tidal Investments LLC increased its stake in Labcorp Holdings Inc. by 12.4% during the second quarter, bringing its total holdings to 30,559 shares valued at approximately $8.6 million. This comes as Labcorp exceeded earnings expectations, reaffirmed its 2026 adjusted EPS guidance, and several other institutional investors also increased their positions. Despite a recent stock decline, analysts maintain a "Moderate Buy" consensus for Labcorp.
National Pension Service Sells 146,486 Shares of Labcorp Holdings Inc. $LH
The National Pension Service reduced its stake in Labcorp Holdings Inc. by 77.2% during the second quarter, selling 146,486 shares and retaining 43,150 shares valued at approximately $12.1 million. Despite this, institutional investors still own about 95.94% of the company. Labcorp recently beat analyst EPS estimates, reported a 5.8% increase in revenue, and reaffirmed its 2026 adjusted EPS guidance, while setting long-term revenue growth targets through 2029.
